drugset
Drugs / Multi-peptide CMV-Modified Vaccinia Ankara Vaccine
last change Jul 2026 re-read 2 minutes ago

Multi-peptide CMV-Modified Vaccinia Ankara Vaccine

also known as CMV-MVA Triplex Vaccine · Multi-antigen CMV-Modified Vaccinia Ankara Vaccine · multi-CMV epitope modified vaccinia Ankara vaccine

Vaccine

Developed for
cytomegalovirus infection · acute lymphoblastic leukemia · diffuse large B-cell lymphoma · high grade B-cell lymphoma · mantle cell lymphoma
Investigated by
City of Hope Medical Center · National Cancer Institute (NCI) · Masonic Cancer Center, University of Minnesota

Trials 10 · a red edge is where a trial was stopped

today NCT07020533 · Ph 1 NCT06735690 · Ph 0 NCT06059391 · Ph 2 NCT05801913 · Ph 1 NCT05432635 · Ph 1 NCT03438344 · Ph 2 NCT03383055 · Ph 1 NCT03560752 · Ph 1 NCT03354728 · Ph 1/2 NCT01941056 · Ph 1
2014201520162017201820192020202120222023202420252026202720282029
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 01 trial
Phase 0 NCT06735690 Dec 2025 → Mar 2029 expected acute lymphoblastic leukemia City of Hope Medical Center Recruiting No outcome recorded
Phase 16 trials
Phase 1 NCT07020533 May 2026 → May 2028 expected Hodgkins lymphoma, acute myeloid leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, leukemia, myeloid, accelerated-phase +3 City of Hope Medical Center Recruiting No outcome recorded
Phase 1 NCT05801913 Sep 2023 → Mar 2028 expected high grade B-cell lymphoma City of Hope Medical Center Recruiting No outcome recorded
Phase 1 NCT05432635 Aug 2023 → Mar 2028 expected diffuse large B-cell lymphoma, mantle cell lymphoma City of Hope Medical Center Recruiting No outcome recorded
Phase 1 NCT03383055 Nov 2018 → Jul 2021 plasma cell myeloma Masonic Cancer Center, University of Minnesota Completed No outcome recorded
Phase 1 NCT03560752 Aug 2018 → Jan 2022 overdue Hodgkins lymphoma, acute myeloid leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, cytomegalovirus infection +5 City of Hope Medical Center Active not recruiting No outcome recorded
Phase 1 NCT01941056 Jan 2014 → Jul 2017 cytomegalovirus infection City of Hope Medical Center Completed No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT03354728 May 2018 → Dec 2026 expected cytomegalovirus infection, disease related to hematopoietic stem cell transplant City of Hope Medical Center Recruiting No outcome recorded
Phase 22 trials
Phase 2 NCT06059391 Jul 2024 → Jan 2028 expected B-cell chronic lymphocytic leukemia, Hodgkins lymphoma, acute myeloid leukemia, chronic myeloid leukemia +2 City of Hope Medical Center Recruiting No outcome recorded
Phase 2 NCT03438344 Dec 2018 → Dec 2021 Hodgkins lymphoma, acute myeloid leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, disease related to hematopoietic stem cell transplant +3 City of Hope Medical Center Withdrawn No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 10 sources stand behind the page.

FieldValueCited text
Known as Multi-peptide CMV-Modified Vaccinia Ankara Vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT03560752 ↗
5

NCT06059391 ↗

NCT06735690 ↗

NCT07020533 ↗

NCT05801913 ↗

NCT05432635 ↗
Known as CMV-MVA Triplex Vaccine “CMV-MVA Triplex Vaccine” NCT03354728 ↗
1

NCT03383055 ↗
Known as Multi-antigen CMV-Modified Vaccinia Ankara Vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT03438344 ↗
Known as multi-CMV epitope modified vaccinia Ankara vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT01941056 ↗
Action Deplete “Vaccines such as CMV-MVA triplex are made from gene-modified viruses and may help the body build an effective immune response to kill cancer cells.” NCT05432635 ↗
Modality Vaccine “multi-CMV epitope modified vaccinia Ankara vaccine” NCT01941056 ↗
Route Intramuscular “Participants receive multi-CMV epitope modified vaccinia Ankara vaccine intramuscularly (IM) followed by a booster injection 28 days later in the absence of unacceptable toxicity.” NCT01941056 ↗